EGFR and HER2 Expression in advanced Biliary Tract Cancer

Introduction: Patients with biliary tract cancer (BTC) are resectable with curative intent in only approx. 20–30% at time of diagnosis. Advanced BTC has a dismal prognosis with a mean overall survival of 7–8 months. Chemotherapy is widely used with little benefit. New treatment options are therefore needed. Growths factors are involved in the carcinogenesis of various tumortypes and are used as therapeutic targets. Little is known about the pathogenic role and potential therapeutic value of the Epidermal Growth Factor Receptor (EGFR) and the Human Epidermal Growth Factor Receptor 2 (HER2) in advanced BTC. Method…